TY - JOUR
T1 - Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: Results of the worldwide, cross-sectional ASAS-PerSpA study
AU - López-Medina, Clementina
AU - Molto, Anna
AU - Sieper, Joachim
AU - Duruöz, Tuncay
AU - Kiltz, Uta
AU - Elzorkany, Bassel
AU - Hajjaj-Hassouni, Najia
AU - Burgos-Vargas, Ruben
AU - Maldonado-Cocco, José
AU - Ziade, Nelly
AU - Gavali, Meghna
AU - Navarro-Compan, Victoria
AU - Luo, Shue-Fen
AU - Monti, Sara
AU - Tae-Jong, Kim
AU - Kishimoto, Mitsumasa
AU - Pimentel-Santos, F. M.
AU - Gu, Jieruo
AU - Schiotis, Ruxandra
AU - van Gaalen, Floris A.
AU - Geher, P. l
AU - Magrey, Marina
AU - Ibáñez Vodnizza, Sebastián E.
AU - Bautista-Molano, Wilson
AU - Maksymowych, Walter
AU - Machado, Pedro M.
AU - Landewé, Robert
AU - van der Heijde, Desirée
AU - Dougados, Maxime
N1 - Funding Information:
Funding This study was conducted under the umbrella of ASAS with unrestricted grant of AbbVie, Pfizer, Lilly, Novartis, UCB, Janssen and Merck. The funders did not have any role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript and decision to submit the manuscript for publication. PMM is supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC).
Publisher Copyright:
© Author(s) (or their employer(s)) 2021.
PY - 2021/1/18
Y1 - 2021/1/18
N2 - Objectives: To characterise peripheral musculoskeletal involvement in patients with spondyloarthritis (SpA) including psoriatic arthritis (PsA), across the world. Methods: Cross-sectional study with 24 participating countries. Patients with a diagnosis of axial SpA (axSpA), peripheral SpA (pSpA) or PsA according to their rheumatologist were included. The investigators were asked which diagnosis out of a list of six (axSpA, PsA, pSpA, inflammatory bowel disease-associated SpA, reactive arthritis or juvenile SpA (Juv-SpA)) fitted the patient best. Peripheral manifestations (ie, peripheral joint disease, enthesitis, dactylitis and root joint disease), their localisation and treatments were evaluated. Results: A total of 4465 patients were included (61% men, mean age 44.5 years) from four geographic areas: Latin America (n=538), Europe plus North America (n=1677), Asia (n=975) and the Middle East plus North Africa (n=1275). Of those, 78% had ever suffered from at least one peripheral musculoskeletal manifestation; 57% had peripheral joint disease, 44% had enthesitis and 15% had dactylitis. Latin American had far more often peripheral joint disease (80%) than patients from other areas. Patients with PsA had predominantly upper limb and small joint involvement (52%). Hip and shoulder involvement was found in 34% of patients. The prevalence of enthesitis ranged between 41% in patients with axSpA and 65% in patients with Juv-SpA. Dactylitis was most frequent among patients with PsA (37%). Conclusion: These results suggest that all peripheral features can be found in all subtypes of SpA, and that differences are quantitative rather than qualitative. In a high proportion of patients, axial and peripheral manifestations coincided. These findings reconfirm SpA clinical subtypes are descendants of the same underlying disease, called SpA.
AB - Objectives: To characterise peripheral musculoskeletal involvement in patients with spondyloarthritis (SpA) including psoriatic arthritis (PsA), across the world. Methods: Cross-sectional study with 24 participating countries. Patients with a diagnosis of axial SpA (axSpA), peripheral SpA (pSpA) or PsA according to their rheumatologist were included. The investigators were asked which diagnosis out of a list of six (axSpA, PsA, pSpA, inflammatory bowel disease-associated SpA, reactive arthritis or juvenile SpA (Juv-SpA)) fitted the patient best. Peripheral manifestations (ie, peripheral joint disease, enthesitis, dactylitis and root joint disease), their localisation and treatments were evaluated. Results: A total of 4465 patients were included (61% men, mean age 44.5 years) from four geographic areas: Latin America (n=538), Europe plus North America (n=1677), Asia (n=975) and the Middle East plus North Africa (n=1275). Of those, 78% had ever suffered from at least one peripheral musculoskeletal manifestation; 57% had peripheral joint disease, 44% had enthesitis and 15% had dactylitis. Latin American had far more often peripheral joint disease (80%) than patients from other areas. Patients with PsA had predominantly upper limb and small joint involvement (52%). Hip and shoulder involvement was found in 34% of patients. The prevalence of enthesitis ranged between 41% in patients with axSpA and 65% in patients with Juv-SpA. Dactylitis was most frequent among patients with PsA (37%). Conclusion: These results suggest that all peripheral features can be found in all subtypes of SpA, and that differences are quantitative rather than qualitative. In a high proportion of patients, axial and peripheral manifestations coincided. These findings reconfirm SpA clinical subtypes are descendants of the same underlying disease, called SpA.
KW - ankylosing
KW - arthritis
KW - juvenile
KW - psoriatic
KW - spondylitis
UR - https://www.scopus.com/pages/publications/85100225971
U2 - 10.1136/rmdopen-2020-001450
DO - 10.1136/rmdopen-2020-001450
M3 - Article
C2 - 33462157
SN - 2056-5933
VL - 7
JO - RMD open
JF - RMD open
IS - 1
M1 - e001450
ER -